Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.44 |
| ▸ | MMP9 | P14780 | 4/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534117 | 0.85 | MMP1 (0.40) | MMP1MMP9MMP13MAPTMCHR1 | |
| SCHEMBL3538685 | 0.84 | LCK (0.45) | HRH3ALDH1A1 | |
| SCHEMBL3537912 | 0.83 | PPARG (0.37) | MMP1MMP13ADAM17MAPTALDH1A1 | |
| SCHEMBL3537088 | 0.78 | LTA4H (0.43) | HRH3KCNH2LTA4HMCHR1 | |
| SCHEMBL3535912 | 0.78 | LSS (0.38) | HRH3MAPTLTA4H | |
| SCHEMBL3537108 | 0.78 | TBXAS1 (0.41) | ALDH1A1 | |
| SCHEMBL1023173 | 0.75 | MMP1 (0.56) | MMP1MMP9MMP13HRH3POLB | |
| SCHEMBL1023175 | 0.74 | ESR1 (0.55) | MMP1MMP9HRH3POLBMAPT | |
| SCHEMBL3532190 | 0.73 | LTA4H (0.41) | MMP1MMP9MMP13HRH3POLB | |
| SCHEMBL3535505 | 0.73 | MMP1 (0.55) | MMP1MMP9MMP13HRH3ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | MMP1 9/4885MMP9 1/4885MMP13 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.